Long-term maintenance of response across multiple fibromyalgia symptom domains in a randomized withdrawal study of pregabalin

Clinical Journal of Pain

Volumn 28, Issue 7, 2012, Pages 609-614

  Pauer, Lynne ^a   Atkinson, Gary ^b   Murphy, T Kevin ^a   Petersel, Danielle ^a   Zeiher, Bernhardt ^a  

^a PFIZER INC   (United States)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

fatigue; fibromyalgia; pain; pregabalin; sleep

Indexed keywords

PREGABALIN;

ADULT; ANXIETY DISORDER; ARTICLE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FIBROMYALGIA; FIBROMYALGIA IMPACT QUESTIONNAIRE; FUNCTIONAL ASSESSMENT; HUMAN; INCIDENCE; INSOMNIA; KAPLAN MEIER METHOD; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MCGILL PAIN QUESTIONNAIRE; MEDICAL OUTCOMES STUDY SLEEP SCALE SLEEP DISTURBANCE SUBSCALE; MONOTHERAPY; NAUSEA; PAIN; PATIENT COMPLIANCE; PATIENT GLOBAL IMPRESSION OF CHANGE; POST HOC ANALYSIS; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RATING SCALE; SHORT FORM 36; SHORT FORM 36 VITALITY SCALE; SLEEP DISORDER; SYMPTOM; TREATMENT RESPONSE;

ANALGESICS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FATIGUE; FEMALE; FIBROMYALGIA; FOLLOW-UP STUDIES; GAMMA-AMINOBUTYRIC ACID; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PAIN MEASUREMENT; SLEEP DISORDERS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84864662290     PISSN: 07498047     EISSN: 15365409     Source Type: Journal    
DOI: 10.1097/AJP.0b013e31823dd315     Document Type: Article

References (23)

1. Bennett RM. Fibromyalgia. In: Wall PD, Melzack R, eds. Textbook of Pain. 4th ed. London: Harcourt Publishers Churchill Livingstone; 1999:579-601.
2. Clauw DJ, Crofford LJ. Chronic widespread pain and fibromyalgia: what we know, and what we need to know. Best Pract Res Clin Rheumatol. 2003;17:685-701.
3. Mease P. Fibromyalgia syndrome: review of clinical presentation, pathogenesis, outcome measures, and treatment. J Rheumatol. 2005;75(suppl):6-21. (Pubitemid 41113954)
4. Wolfe F, Smythe HA, Yunus MB, et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the multicenter criteria committee. Arthritis Rheum. 1990;33:160-172. (Pubitemid 20098653)
5. Mease PJ, Arnold LM, Crofford LJ, et al. Identifying the clinical domains of fibromyalgia: contributions from clinician and patient Delphi exercises. Arthritis Rheum. 2008;59:952-960. (Pubitemid 351990991)
6. Field MJ, Cox PJ, Stott E, et al. Identification of the alpha2-delta-1 subunit of voltage-dependent calcium channels as a molecular target for pain mediating the analgesic actions of pregabalin. Proc Natl Acad Sci USA. 2006;103:17537-17542. (Pubitemid 44789004)
7. Dooley DJ, Donovan CM, Pugsley TA. Stimulus-dependent modulation of (3)Hnorepinephrine release from rat neocortical slices by gabapentin and pregabalin. J Pharmacol Exp Ther. 2000;295:1086-1093.
8. Dooley DJ, Mieske CA, Borosky SA. Inhibition of K(+)-evoked glutamate release from rat neocortical and hippocampal slices by gabapentin. Neurosci Lett. 2000;280:107-110. (Pubitemid 30109144)
9. Dooley DJ, Taylor CP, Donevan S, et al. Ca2+ channel alpha2delta ligands: novel modulators of neurotransmission. Trends Pharmacol Sci. 2007;28:75-82. (Pubitemid 46161838)
10. Fehrenbacher JC, Taylor CP, Vasko MR. Pregabalin and gabapentin reduce release of substance P and CGRP from rat spinal tissues only after inflammation or activation of protein kinase C. Pain. 2003;105:133-141. (Pubitemid 37162482)
11. Fink K, Dooley DJ, Meder WP, et al. Inhibition of neuronal Ca(2+) influx by gabapentin and pregabalin in the human neocortex. Neuropharmacology. 2002;42:229-236. (Pubitemid 34137026)
12. Joshi I, Taylor CP. Pregabalin action at a model synapse: binding to presynaptic calcium channel alpha2-delta subunit reduces neurotransmission in mice. Eur J Pharmacol. 2006;553: 82-88. (Pubitemid 44779589)
13. Micheva KD, Taylor CP, Smith SJ. Pregabalin reduces the release of synaptic vesicles from cultured hippocampal neurons. Mol Pharmacol. 2006;70:467-476. (Pubitemid 44092307)
14. Arnold LM, Russell IJ, Diri EW, et al. A 14-week, randomized, double-blinded, placebo-controlled monotherapy trial of pregabalin in patients with fibromyalgia. J Pain. 2008; 9:792-805.
15. Crofford LJ, Rowbotham MC, Mease PJ, et al. Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2005;52:1264-1273. (Pubitemid 40530135)
16. Mease PJ, Russell IJ, Arnold LM, et al. A randomized, doubleblind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia. J Rheumatol. 2008; 35:502-514. (Pubitemid 351374429)
17. Crofford LJ, Mease PJ, Simpson SL, et al. Fibromyalgia relapse evaluation and efficacy for durability of meaningful relief (FREEDOM): a 6-month, double-blind, placebocontrolled trial with pregabalin. Pain. 2008;136:419-431.
18. Dworkin RH, Turk DC, Wyrwich KW, et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain. 2008;9: 105-121. (Pubitemid 351147828)
19. Farrar JT, Young JP Jr., LaMoreaux L, et al. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain. 2001;94:149-158. (Pubitemid 33016608)
20. Melzack R. The short-form McGill Pain Questionnaire. Pain. 1987;30:191-197. (Pubitemid 18029372)
21. Bennett RM, Friend R, Jones KD, et al. The Revised Fibromyalgia Impact Questionnaire (FIQR): validation and psychometric properties. Arthritis Res Ther. 2009;11:R120.
22. Cappelleri JC, Bushmakin AG,McDermott AM, et al. Measurement properties of the Medical Outcomes Study Sleep Scale in patients with fibromyalgia. Sleep Med. 2009;10:766-770.
23. Bjorner JB, Wallenstein GV, Martin MC, et al. Interpreting score differences in the SF-36 Vitality scale: using clinical conditions and functional outcomes to define the minimally important difference. Curr Med Res Opin. 2007;23:731-739. (Pubitemid 46631476)